TWI684450B - 猝倒症之治療 - Google Patents
猝倒症之治療 Download PDFInfo
- Publication number
- TWI684450B TWI684450B TW108107074A TW108107074A TWI684450B TW I684450 B TWI684450 B TW I684450B TW 108107074 A TW108107074 A TW 108107074A TW 108107074 A TW108107074 A TW 108107074A TW I684450 B TWI684450 B TW I684450B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- patent application
- item
- application scope
- mirror image
- Prior art date
Links
- 208000001573 Cataplexy Diseases 0.000 title claims abstract description 75
- 238000011282 treatment Methods 0.000 title description 28
- 150000001875 compounds Chemical class 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 11
- 201000003631 narcolepsy Diseases 0.000 claims description 11
- 239000007937 lozenge Substances 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 102100037505 Secretin Human genes 0.000 claims description 2
- 108010086019 Secretin Proteins 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229960002101 secretin Drugs 0.000 claims description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001662 Subependymal Glioma Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000030819 subependymoma Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract description 8
- -1 D-camphorsulfonate Chemical compound 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 150000002148 esters Chemical class 0.000 description 25
- UCTRAOBQFUDCSR-SECBINFHSA-N [(2r)-2-amino-3-phenylpropyl] carbamate Chemical compound NC(=O)OC[C@H](N)CC1=CC=CC=C1 UCTRAOBQFUDCSR-SECBINFHSA-N 0.000 description 22
- 229940079593 drug Drugs 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- VWYANPOOORUCFJ-UHFFFAOYSA-N alpha-Fernenol Chemical compound CC1(C)C(O)CCC2(C)C3=CCC4(C)C5CCC(C(C)C)C5(C)CCC4(C)C3CCC21 VWYANPOOORUCFJ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960004823 armodafinil Drugs 0.000 description 2
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 229960002430 atomoxetine Drugs 0.000 description 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004461 rapid eye movement Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229960003928 sodium oxybate Drugs 0.000 description 2
- 239000012439 solid excipient Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- YFVKHKCZBSGZPE-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one Chemical compound CCCNC(C)C(=O)C1=CC=C2OCOC2=C1 YFVKHKCZBSGZPE-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- UCTRAOBQFUDCSR-UHFFFAOYSA-N NC(Cc1ccccc1)COC(N)=O Chemical compound NC(Cc1ccccc1)COC(N)=O UCTRAOBQFUDCSR-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LVRBGYZRSDXBKM-SECBINFHSA-N [(2R)-2-amino-3-phenylpropyl]carbamic acid Chemical group OC(=O)NC[C@H](N)CC1=CC=CC=C1 LVRBGYZRSDXBKM-SECBINFHSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- XAMAATKKOCZRPP-UHFFFAOYSA-N dodecyl hydrogen sulfate;propanoic acid Chemical compound CCC(O)=O.CCCCCCCCCCCCOS(O)(=O)=O XAMAATKKOCZRPP-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000044 progesterone antagonist Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/02—Carbamic acids; Salts of carbamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本發明係關於對有需要之個體治療猝倒症的方法，包括給予個體治療有效劑量之某些胺甲酸酯化合物。
Description
本發明係關於對有需要之個體治療猝倒症的方法，包括給予個體治療有效劑量之某些胺甲酸酯(carbamate)化合物。
猝倒症為突然及短暫性發作之肌肉張力喪失，時常由情緒諸如笑、害怕、憤怒、挫折、煩惱、焦燥、難堪及悲傷所引起。猝倒症之突然肌肉張力喪失係與睡眠期間與快速動眼(REM)有關聯之肌肉鬆弛相似，但係發生在覺醒期間。猝倒發作為突然的發病且局部化於特定之肌群或身體部位。個體在發作期間神志清明；猝倒症發病時總是維持清醒。可能發生全面發作並造成伴隨姿勢性虛脫之完全肌肉麻痺且可能受到傷害。然而，因為跌倒是緩慢且漸進的所以有姿勢性虛脫之患者往往具有避免傷害之能力。較通常限定之猝倒發作在包含頭與臉部、頸部及上肢，及較少在稱為“跪倒”之下肢。發作可持續數秒鐘至十分鐘，且可能每星期發生數次。有些病人發生猝倒持續狀態，或周期性之重複肌肉張力喪失，且可持續幾小時或幾天。
猝倒症為罕見疾病(社會中之盛行率為少於10,000分之5)，但是卻侵襲大約70%之患猝睡症者。然而，在有些例子中，猝倒症之發生並未伴隨猝睡症發生。再者，多於30%之猝睡
症患者可能從未經歷猝倒。猝倒症之確實成因未知，但是症狀與遭受強烈情緒及神經傳導物質下視丘分泌素濃度之減少有強力關聯。一般認為猝倒症係由於特定之腦部損害造成下視丘分泌素神經傳導物質之耗盡而伴隨繼發。猝倒症亦可能為某些藥物，諸如選擇性血清素再吸收抑制劑(SSRI)抗憂鬱劑，停藥後之副作用。
無論是否與猝睡症或其他成因有關聯，猝倒症會造成傷殘並有潛在的危險。不管成因如何，猝倒症與種種交通及工傷事故有關聯並造成工作績效下降及相當的主觀性憂傷。可用以減少或排除猝倒症之治療藥劑不僅對個別患者而且對公共健康與安全具有重要意義。
本發明係針對有需要之個體治療猝倒症的方法，包括給予個體治療有效劑量之式(I)化合物或其醫藥上可接受之鹽或酯：
其中R為選自由1至8個碳原子之烷基、鹵素、含有1至3個碳原子之烷氧基、硝基、羥基、三氟甲基及含有1至3個碳原子之硫代烷氧基所構成之群組之一基團；x為0至3之整數，當x為2或3時附帶條件係R可為相同或不同；R1及R2可為彼此相同或不同，且獨立選自由氫、1至8個碳原子之低碳數烷基、芳基、芳基烷基、3至7個碳原子之環烷基所構成之群組；或R1及R2可連結而形成視需要經選自由烷基及芳基所構成之群組之一基團取代
之5至7-員雜環，其中該雜環可包括1至2個氮原子及0至1個氧原子，其中該氮原子不直接彼此連接或與氧原子連接。
本發明之具體例包含對有需要之個體治療猝倒症的方法，該方法包括給予個體治療有效劑量之實質上無其他鏡像異構物之式(I)之鏡像異構物，或其中一種式(I)之鏡像異構物佔多數之鏡像異構物混合物之步驟。
一些具體例中，式(I)化合物為式(Ia)化合物：
或其醫藥上可接受之鹽或酯。
一些具體例中，式(I)化合物為式(Ib)化合物：
或其醫藥上可接受之鹽或酯。此化合物命名為(R)-胺甲酸(β-胺基-苯丙基)酯或O-胺甲醯基-(D)-苯丙胺醇及或者稱為ADX-N05、SKL-N05、YKP10A及R228060。
本發明之具體例包含實質上無其他鏡像異構物之式I之鏡像異構物，或其中一種式(I)之鏡像異構物佔多數之鏡像異構物混合物作為製備治療猝倒症之藥物之用途。
以下將參考附帶之描述及實施例而說明本發明，其中顯示發明之具體例。然而，本發明可由許多不同形式體現且不應當解釋為限制於本文所列之具體例。更確切地說，提供這些具體例而使得本揭露更為徹底及完整，而且將全面傳達本發明之範疇於所屬技術領域具通常知識者。
除非另有說明，否則本文使用之技術術語或科學術語具有一般本發明所屬技術領域具通常知識者通常瞭解之意義。本發明之說明中使用之術語僅用於說明特定具體例之目的而非意指限制本發明。
除非上下文另有指明，否則要特別指明本文所說明之發明的各種不同特徵可以任何組合而使用。再者，本發明亦涵蓋，在一些發明之具體例中可排除或略去本文所提出之任何特徵或特徵之組合。舉例說明，如果說明書陳述組成物包括成分A、B及C，係意欲指任何A、B及C或其組合可單獨地或任意組合地略去或放棄。
如本文所使用，“一(a)”、“一(an)”或“該(the)”可意指一個或多於一個。例如，“一(a)”細胞意指單一細胞或多數細胞。
亦如本文所使用，“及/或”意指且包含一種或多種相關表列項目之任何及所有可能組合，以及當解釋為兩者擇一(“或”)時則無組合。
術語“約”，如本文所使用，當意指可測量值諸如劑量(如，化合物量)等，則意為包含所指定量之±20%、±10%、±
5%、±1%、±0.5%或甚至±0.1%之變化。
術語“包括(comprise)”、“包括(comprises)”及“包括(comprising)”，如本文所使用，明確說明所述之特徵、整數、步驟、操作、元件及/或成分之存在，但並不排除一種或多種其他特徵、整數、步驟、操作、元件、成分及/或其群組之存在或添加。
如本文所使用，連接詞“基本上由…組成”意指申請專利之範圍係包含專利申請中所述之指定物質或步驟“而彼等不會重大影響所要求保護之發明之基本及新穎特性”。請參照，In re Herz,537 F.2d 549,551-52,190 U.S.P.Q.461,463(CCPA 1976)(原文強調)；亦請參照MPEP § 2111.03。因此，使用於申請專利範圍或本發明之說明時，術語“基本上由…組成”並非意指相當於“包括”。
如本文所使用，術語“增加(increase)”、“增加(increases)”、“增加(increased)”、“增加(increasing)”及相似之術語表明至少約25%、50%、75%、100%、150%、200%、300%、400%、500%或更多之提高。
如本文所使用，術語“減少(reduce)”、“減少(reduces)”、減少(reduced)”、“減少(reduction)”及相似之術語表明至少約5%、10%、15%、20%、25%、35%、50%、75%、80%、85%、90%、95%、97%或更多之降低。特別的具體例中，此減少造成無或實質上無(即，無意義的量，如，少於約10%或甚至5%)可檢測出之活性或量。
“有效量”如本文所使用，意指化合物、組成物及
/或本發明調配物之量，而該量足夠產生可為治療及/或有益效用之所需效用。有效量隨年齡、個體之一般狀況、預治療症狀之嚴重性、給予之特別藥劑、治療期限、任何同時治療之性質、使用之醫藥上可接受之載體及所屬技術領域具通常知識者之知識及專門技術範圍內之類似因素而變化。視情況，所屬技術領域熟練之人員可經由參考有關文本及文獻及/或使用一般實驗而測定任何個別實例中之“有效量”。
術語“治療(treat)”、“治療(treating)或“治療(treatment of)”(及其文法上之變化)的意思為個體症狀之嚴重性降低，至少部分改進或改善及/或達到至少一種臨床症狀之一些緩解、減輕或降低及/或得到疾病或障礙進展之延緩。關於猝倒症，該術語意指發作次數之減少、發作期間之減短，及/或發作嚴重性之降低。例如，治療可產生至少每星期約20%猝倒事件次數之降低，如，至少約降低30%、40%、50%、60%、70%、80%或更多。
如本文所使用之“治療有效”量為足夠治療(如本文所定義)個體之量。所屬技術領域具通常知識者應瞭解治療效用不需要是完全或治癒，只要可提供個體一些益處。
本發明之“個體”包含任何已經或懷疑患有猝倒症之動物。此種個體通常為哺乳類動物個體(如，供實驗用動物諸如大鼠、小鼠、天竺鼠、兔、靈長類等)、農場或商業動物(如，牛、馬、山羊、驢、綿羊等)或家畜(如，貓、狗、雪貂等)。特別的具體例中，個體為靈長類個體、非人類之靈長類個體(如，黑猩猩、狒狒、猴子、大猩猩等)或人類。某些具體例中，本發明之個體可為已知有或認為患有猝倒症之個體。發明之個體可為已知有或認
為有患猝倒症風險之個體。替代地，根據本發明之個體亦可包含事先不知或不懷疑患有猝倒症之個體。發明之具體例中個體具有或懷疑有猝睡症。個體包含任何年齡之雄性及/或雌性，包含新生、幼年、成熟及老年個體。
本發明方法之“有需要之個體”可為已知患有猝倒症之個體、懷疑患有猝倒症之個體或有增加患猝倒症風險之個體。一些具體例中，“有需要之個體”為有中度或重度猝倒症者，如，每星期有3次或較多次猝倒事件，如，每星期有4、5、6、7、8、9或10次或較多次猝倒事件之個體。
術語“醫藥上可接受之鹽類或酯類”意指本發明所採用化合物之非毒性鹽類或酯類，通常經由使游離酸與適當之有機或無機鹼反應或使游離鹼與適當之有機或無機酸反應而製備該鹽類或酯類。此種鹽類之實例包含，但不限制於，乙酸鹽、苯磺酸鹽、苯甲酸鹽、碳酸氫鹽、硫酸氫鹽、酒石酸氫鹽、硼酸鹽、溴化物、鈣、依地酸鈣、右旋樟腦磺酸鹽、碳酸鹽、氯化物、克拉維酸鹽(clavulanate)、檸檬酸鹽、二鹽酸鹽、依地酸鹽、乙二磺酸鹽、丙酸酯月桂基硫酸鹽、乙磺酸鹽、反丁烯二酸鹽、葡庚糖酸鹽、葡萄糖酸鹽、麩胺酸鹽、乙醇醯基對胺基苯胂酸鹽(glycollylarsanilate)、己基間苯二酚酸鹽(hexylresorcinate)、海巴明(hydrabamine)、氫溴酸鹽、鹽酸鹽、羥萘甲酸鹽、碘化物、異硫羥酸鹽(isothionate)、乳酸鹽、乳醣酸鹽、月桂酸鹽、蘋果酸鹽、順丁烯二酸鹽、苯乙醇酸鹽、甲磺酸鹽、溴化甲烷、甲基硝酸、硫酸甲酯、粘酸鹽、萘磺酸鹽、硝酸鹽、油酸鹽、草酸鹽、雙羥萘酸鹽、棕櫚酸鹽、泛酸鹽、磷酸鹽/二磷酸鹽、聚半乳醣醛酸鹽、
鉀、水楊酸鹽、鈉、硬脂酸鹽、次乙酸鹽、琥珀酸鹽、單寧酸鹽、酒石酸鹽、8-氯茶鹼鹽、甲苯磺酸鹽、三乙基碘化物及戊酸鹽。
如本文所使用，術語化合物、治療劑或已知藥物與本發明化合物之“合併給藥”或“組合給藥”意思為在這樣的時間點給予已知藥物治療或藥物，並加上本發明之一種或多種化合物而使已知藥物及化合物皆具有治療效果。在一些實例中這種治療效果是相乘的。此種合併給藥可包含給藥本發明化合物之同時(即，在相同時間)、之前或之後給藥已知藥物。所屬技術領域具通常知識者，應不難決定給藥特別藥物及本發明化合物之適當時間點、順序及劑量。
此外，一些具體例中，本發明化合物或彼等之鹽類或酯類係經單獨或彼此相組合或與上述之一種或多種其他治療藥物組合，而使用於製造其目的為提供給有需要之患者或個體治療猝倒症之藥物。
本發明部分地係基於式(I)之苯基烷基胺基胺甲酸酯具有新穎及獨特藥理性質之發現。這些化合物顯示對DREM及猝倒症具有益效用。雖然尚未完全瞭解作用之確切機制，一般相信這些化合物並非經由與大部分其他已知興奮劑相同之機制而產生彼等效用。因而式(I)化合物特別適合使用於治療猝倒症。因此，不管疾病之確切病因為何，這些化合物可安全地使用於此目的而提供猝倒症之有效治療。
發明之一方面係關於對有需要之個體治療猝倒症的方法，包括給予個體治療有效量之式(I)化合物：
或其醫藥上可接受之鹽或酯；其中R為選自由1至8個碳原子之低碳數烷基、鹵素、含有1至3個碳原子之烷氧基、硝基、羥基、三氟甲基及含有1至3個碳原子之硫代烷氧基所構成之群組之一基團；x為0至3之整數，當x為2或3時附帶條件為R可為相同或不同；R1及R2係獨立選自由氫、1至8個碳原子之低碳數烷基、芳基、芳基烷基及3至7個碳原子之環烷基所構成之群組；或R1及R2可連結而形成視需要可經選自由烷基及芳基所構成之群組之一基團取代之5至7-員雜環，其中該雜環可包括1至2個氮原子及0至1個氧原子，其中該氮原子不直接彼此連接或與氧原子連接。
一般瞭解所屬技術領域具通常知識者可選擇本發明化合物之取代基及取代類型而提供化學性穩定及易於由所屬領域已知之技術以及本文所提供之技術而合成之化合物。
具體例中，式(I)化合物為式(Ia)化合物：
或其醫藥上可接受之鹽或酯。
具體例中，式(I)化合物為(D)鏡像異構物，其中R1及R2為氫及x為0(化合物(Ib))。
本發明包含單離之式(I)化合物之鏡像異構物(如，式(Ia)或(Ib)化合物)之用途。具體例中，使用包括單離之式(I)之S-鏡像異構物的醫藥組成物而提供對個體之治療。另一個具體例中，使用包括單離之式(I)之R-鏡像異構物的醫藥組成物而提供對個體之治療。
本發明亦包含式(I)之鏡像異構物混合物之用途。在本發明之一方面，一種鏡像異構物佔大多數。在混合物中佔大多數之鏡像異構物係以較任何存在於混合物中之其他鏡像異構物更多量存在於混合物中之鏡像異構物，如，以大於50%之量。在一方面，一種鏡像異構物佔多數達90%或達91%、92%、93%、94%、95%、96%、97%或98%或更多。具體例中，在包括式(I)化合物之組成物中佔多數之鏡像異構物為式(I)之S-鏡像異構物。
本發明提供使用式(I)表示之化合物之鏡像異構物及鏡像異構物混合物之方法。式(I)之胺甲酸酯鏡像異構物在苯甲基位置含有不對稱手性碳原子，其為鄰接苯環之第二個脂族碳。
經單離之鏡像異構物為實質上無對應之鏡像異構物者。因此，單離之鏡像異構物意指通過分離技術而分離或經由摒
除對應鏡像異構物而製備之化合物。
術語“實質上無”，如本文所使用，意指化合物由顯著較大部分之一種鏡像異構物所構成。較佳具體例中，化合物包含至少約90重量%之一種鏡像異構物。發明之其他具體例中，化合物包含至少約99重量%之一種鏡像異構物。
可經由熟練之技術人員所熟知之方法合成式(I)化合物。可經由用適當之無機酸或有機酸(HX)在適當之溶劑中處理化合物或經由所屬技術領域具通常知識者所熟知之其他方法而製造式(I)化合物之鹽類及酯類。
合成式(I)化合物之詳細反應圖示以及製造特定化合物之代表性實例已說明於U.S.Pat.No.5,705,640、U.S.Pat.No.5,756,817、U.S.Pat.No.5,955,499、U.S.Pat.No.6,140,532，通過引用將其全部內容併入本文中。
從式(I)明顯地有些本發明化合物具有至少一個且可能有多個不對稱碳原子。意指本發明在其範圍內包含化合物之立體化學性純淨之異構物形態以及彼等之消旋物。可應用所屬領域已知之原理而得到立體化學性純淨之異構物形態。可經由物理分離方法諸如分步結晶及層析技術而分離非鏡像異構物，及可經由與光學活性酸或鹼所成之非鏡像異構物鹽類之選擇性結晶或經由手性層析法而使鏡像異構物彼此分離。亦可從適當之立體化學性純淨之起始物質以合成方式，或使用立體選擇性反應而製造純立體異構物。
製備本發明化合物之任何製程期間，可能需要及/或最好保護任何分子相關之敏感或反應性基團。可經由常用之保
護基方式而達成，諸如Protective Groups in Organic Chemistry,ed.J.F.W.McOmie,Plenum Press,1973及T.W.Greene & P.G.M.Wuts,Protective Groups in Organic Synthesis,Third Edition,John Wiley & Sons,1999中所說明者。可使用所屬領域熟知之方法在合宜之隨後階段移除保護基。
可由任何常用之給藥途徑將化合物給予個體，包含但不限於，口服、口腔、局部、全身(如，經皮、鼻腔或用栓劑)，或非口服(如，肌肉內、皮下或靜脈注射)。直接將化合物給予神經系統之給藥可包含，例如，藉由顱內或椎管(intravertebral)針或者有或無幫浦裝置之導管之遞送而給藥至大腦內、腦室內、側腦室內、鞘內、腦池內、脊柱內或脊柱旁路徑之給藥。隨著給藥途徑，可將式(I)化合物組成任何劑型。例如，適合口服給藥的劑型包含固體劑型，諸如丸劑、囊形片、錠劑、膜衣錠、膠囊、顆粒劑及粉劑(各包含立即釋放、經時釋放及持續釋放配方)。適合口服給藥的劑型亦包含液體劑型，諸如溶液、糖漿、酏劑、乳狀液及懸浮液。此外，適用於非口服給藥之形式包含滅菌溶液、乳狀液及懸浮液。
某些具體例中，本發明之醫藥組成物包括一種或多種式(I)化合物或其鹽或酯而無任何醫藥用載體或賦形劑。其他具體例中，本發明之醫藥組成物包括根據常用醫藥複合技術緊密摻合醫藥用載體之一種或多種式(I)化合物或其鹽或酯。載體為惰性醫藥賦形劑，包含但不限於，黏合劑、懸浮劑、潤滑劑、調味劑、甜味劑、防腐劑、染料及塗層。製備口服劑型之組成物時，可採用任何通常之醫藥用載體。例如，用於液體口服製劑，適合之載
體及添加物包含水、乙二醇、油、酒精、調味劑、防腐劑、著色劑等；用於固體口服製劑，適合之載體及添加物包含澱粉、糖、稀釋劑、製粒劑、潤滑劑、黏合劑、崩解劑等。
組成物之劑型可為錠劑、丸劑、膠囊、半固體、粉劑、持續釋放配方、溶液、懸浮液、乳狀液、糖漿、酏劑、氣霧劑或任何其他適合之組成物；包括至少一種本發明之化合物，視需要與至少一種醫藥上可接受之賦形劑組合。所屬領域一般熟練之技術人員熟知適當之賦形劑，且彼等，可從如Alfonso AR：Remington's Pharmaceutical Sciences,17th ed.,Mack Publishing Company,Easton Pa.,1985，之此類標準參考書目找到調配組成物之方法，通過引用將其所揭露之全部內容併入本文中並用於所有目的。適當之液體載體，特別是用於可注射溶液，包含水、鹽水溶液、葡萄糖水溶液及乙二醇。
可以水性懸浮液形式提供胺甲酸酯化合物。本發明之水性懸浮液可含有胺甲酸酯化合物，且與適合於製造水性懸浮液之賦形劑摻合。此類賦形劑可包含，例如，懸浮劑，諸如羧甲基纖維素鈉、甲基纖維素、羥丙基甲基纖維素、海藻酸鈉、聚乙烯吡咯烷酮、黃蓍膠及阿拉伯膠，及分散劑或潤濕劑諸如天然生成之磷脂(如，卵磷脂)、環氧烷與脂肪酸之縮合產物(如，聚氧伸乙基硬脂酸酯)、環氧乙烷與長鏈脂族醇之縮合產物(如，十七伸乙基氧基鯨臘醇)、環氧乙烷與從脂肪酸和己糖醇衍生之偏酯的縮合產物(如，聚氧伸乙基山梨糖醇單油酸酯)或環氧乙烷與從脂肪酸和己糖醇酐衍生之偏酯的縮合產物(如，聚氧伸乙基去水山梨糖醇單油酸酯)。
水性懸浮液亦可含有一種或多種防腐劑諸如對羥苯甲酸乙酯或對羥苯甲酸正丙酯，一種或多種著色劑，一種或多種調味劑，及一種或多種甜味劑諸如蔗糖、阿斯巴甜或糖精。可調節配方的滲透性。
可將胺甲酸酯化合物懸浮於植物油中諸如花生油、橄欖油、芝麻油或椰子油，或礦物油中諸如液態石蠟，或其等之混合物中，而調配使用於本方法之油性懸浮液。油性懸浮液可含有增稠劑，諸如蜂蠟、硬石蠟或鯨臘醇。可添加甜味劑諸如甘油、山梨醇或蔗糖而提供美味之口服製劑。可添加抗氧化劑諸如抗壞血酸而保存此等配方。可注射油性賦形劑之實例，請參照Minto,J.Pharmacol.Exp.Ther.281：93(1997)。本發明藥物配方亦可為水包油乳狀液之形態。如上述，油相可為植物油或礦物油，或其等之混合物。
適合之乳化劑包含天然生成的膠，諸如阿拉伯膠及黃蓍膠，天然生成之磷脂，諸如大豆卵磷脂，從脂肪酸和己糖醇酐衍生之酯類或偏酯類，諸如去水山梨糖醇單油酸酯，及這些偏酯與環氧乙烷之縮合產物，諸如聚氧伸乙基去水山梨糖醇單油酸酯。乳狀液亦可含有甜味劑及調味劑，如糖漿及酏劑之配方。此類配方亦可含有緩和劑、防腐劑或著色劑。
可將選擇之化合物，單獨或與其他適當之成分組合而製成噴霧劑配方(即，可“霧化”)而可經由吸入給藥。可將噴霧劑配方放入可接受加壓之推進劑中，諸如二氯二氟甲烷、丙烷、氮等。
本發明配方適合非口服給藥，諸如，例如，經由關
節內(在關節內)、靜脈、肌肉內、皮內、腹膜內及皮下途徑，可包含水性及非水性、等張滅菌注射溶液，其可含有抗氧化劑、緩衝劑、抑菌劑，及使得配方與預定接受者之血液等張之溶質，及可包含懸浮劑、助溶劑、增稠劑、安定劑及防腐劑之水性及非水性滅菌懸浮液。可接受之載體及溶劑中可採用的為水及林格氏溶液、等張氯化鈉。此外，習慣上可採用滅菌固定油類作為溶劑或懸浮介質。為此目的可採用任何溫和的固定油包含合成之單或雙甘油酯。此外，同樣亦可使用脂肪酸諸如油酸於製備注射劑。這些溶液為滅菌的且一般不含不想要的物質。
在化合物充分可溶的情況，彼等可直接溶於正常鹽水且可使用或不使用適當之有機溶劑，諸如丙二醇或聚乙二醇。
可在水性澱粉或羧甲基纖維素鈉溶液中或在適當之油，諸如花生油中，形成細碎化合物之分散液。可經由常用、熟知之滅菌技術來滅菌這些配方。配方可含有醫藥上可接受作為要求使近似於生理條件之輔助物質諸如pH調節劑及緩衝劑，毒性調節劑，如，乙酸鈉、氯化鈉、氯化鉀、氯化鈣、乳酸鈉等。
這些配方中之胺甲酸酯化合物濃度可有很大的差異，主要可基於液量、黏稠度、體重等，根據所選擇之給藥特別模式及患者之需求而加以選擇。用於IV給藥，配方可為滅菌注射製劑，諸如滅菌注射水性或油性的懸浮液。可根據已知技術使用適當之分散或潤濕劑及懸浮劑而調配此懸浮液。滅菌注射製劑亦可為在無毒非口服可接受之稀釋劑或溶劑中，諸如1,3-丁二醇溶液，之滅菌注射溶液或懸浮液。推薦的配方可以單位劑量或多劑量之密封容器呈現，諸如安瓿及小玻璃瓶。可從上述種類之滅菌
粉劑、粒劑及錠劑而製備注射溶液。
適合使用於實踐本發明之胺甲酸酯化合物可口服給藥。取決於組成物之類型、單位劑量之大小、賦形劑之種類及其他所屬技術領域熟練之人員熟知之因素，本發明化合物之量可有很大的差異。一般，最終組成物可包括，例如，0.000001重量百分率(% w)至100% w之胺甲酸酯化合物，如，0.00001% w至50% w，而其餘為賦形劑或賦形劑等。
使用所屬領域熟知之醫藥上可接受之載體可調配適合於口服給藥之劑量的口服給藥用藥物配方。此類載體使藥物配方能調配成單位劑型之錠劑、丸劑、粉劑、糖衣錠、膠囊、液體、含片、凝膠、糖漿、漿劑、懸浮液等而適合患者攝食。其他具體例中，可不使用任何醫藥上可接受之載體而調配口服給藥之藥物配方。
適合口服給藥之配方可包含(a)液體溶液，諸如有效量之藥物配方懸浮於稀釋劑，諸如水、鹽水或PEG 400中；(b)膠囊、袋裝粉劑或錠劑，各含有預定量之活性成分，如液體、固體、顆粒或明膠；(c)適當液體中之懸浮液；及(d)適當之乳狀液。
可透過組合本發明化合物與固體賦形劑而得到口服用之藥物製劑，視需要研磨所得混合物，如需要，添加適當之附加化合物後，處理顆粒之混合，而得到錠劑或糖衣錠。適合之固體賦形劑為碳水化合物或蛋白質填料及包含，但不限於糖類，包含乳糖、蔗糖、甘露醇或山梨醇；玉米、小麥、稻米、馬鈴薯或其他植物之澱粉；纖維素諸如甲基纖維素、羥甲基纖維素、羥丙基甲基纖維素或羧甲基纖維素鈉；及膠類包含阿拉伯膠及黃蓍
膠；以及蛋白質諸如明膠及膠原蛋白。
如需要，可添加崩解劑或助溶劑，諸如交聯聚乙烯吡咯烷酮、洋菜、海藻酸或其鹽，諸如海藻酸鈉。錠劑劑型可包含一種或多種乳糖、蔗糖、甘露醇、山梨醇、磷酸鈣、玉米澱粉、馬鈴薯澱粉、微晶纖維素、明膠、膠態二氧化矽、滑石、硬脂酸鎂、硬脂酸，及其他賦形劑、著色劑、填料、黏合劑、稀釋劑、緩衝劑、潤濕劑、防腐劑、調味劑、染劑、崩解劑及醫藥上可相容之載體。含片劑型可包括含於加味劑，如，蔗糖，之活性成分，以及在惰性基質，諸如明膠及甘油中包括活性成分之軟糖錠，或除了活性成分外含有所屬領域習知之載體之蔗糖及阿拉伯膠乳狀液、凝膠等。
亦可以栓劑之形態給予本發明化合物而用於直腸給藥。可將藥物與適當之無刺激性賦形劑混合而製備該等配方，而該賦形劑在常溫為固體但在直腸溫度為液體因而溶解於直腸而釋放藥物。此類物質為可可脂及聚乙二醇。
本發明化合物亦可經鼻腔內、眼內、陰道及直腸內途徑給藥包含栓劑、吹入劑、粉劑及噴霧劑配方(類固醇吸入劑實例，請參照Rohatagi,J.Clin.Pharmacol.35：1187(1995)；Tjwa,Ann.Allergy Asthma Immunol.75：107(1995))。
本發明化合物亦可經皮遞送，經局部途徑，調配成敷藥棒、溶液、懸浮液、乳狀液、凝膠、乳膏、軟膏、糊劑、膠凍劑、塗抹劑、粉劑及噴霧劑。
本發明化合物亦可採用膠囊封裝物質且術語“組成物”可包含與膠囊封裝物質組合作為配方之活性成分，有或沒有
其他載體。例如，本發明化合物亦可作為微球粒遞送而於體內緩慢釋放。具體例中，可經由皮內注射含有藥物(如，黃體素拮抗劑)之微球粒而給藥微球粒，其緩慢地於皮下釋出(請參照Rao,J.Biomater.Sci.Polym.Ed.7：623(1995)；作為生物可降解及注射凝膠配方(請參照，如，Gao,Pharm.Res.12：857(1995))；或，作為用於口服給藥之微球粒(請參照，如，Eyles,J.Pharm.Pharmacol.49：669(1997))。經皮及皮內途徑皆提供數個星期或數個月之持續遞送。本發明化合物之遞送亦可使用扁囊劑(Cachet)。
另一個具體例中，本發明化合物亦可使用與細胞膜融合或經胞吞之脂質體而遞送，即，利用附著於脂質體之配體，而該脂質體連結於造成胞吞作用之細胞之表面膜蛋白受體。亦可以脂質體遞送系統之形態給予活性藥物，諸如單層小微脂粒、單層大微脂粒及多層微脂粒。可從多種磷脂諸如膽固醇、硬脂基胺或磷脂醯膽鹼而形成脂質體。
使用脂質體，特別是在脂質體表面攜帶特定於目標細胞之配體之情況，或是優先導至特定器官之情況，可聚焦於在生物體中胺甲酸酯化合物至目標細胞之遞送(請參照，如，Al-Muhammed,J.Microencapsul.13：293(1996)；Chonn,Curr.Opin.Biotechnol.6：698(1995)；Ostro,Am.J.Hosp.Pharm.46：1576(1989))。
亦可使用與化合物分子偶合之單株抗體作為個別的載體而遞送活性藥物。活性藥物亦可與作為靶向藥物載體之可溶性聚合物偶合。此類聚合物可包含聚乙烯吡咯烷酮、哌喃共聚物、聚羥基丙基甲基丙烯醯胺酚、聚羥基乙基天門冬醯胺酚或經棕櫚
醯基殘基取代之聚環氧乙烷聚離胺酸。再者，活性藥物可與適用於達成控制藥物釋放之一種生物可降解聚合物偶合，例如，聚乳酸、聚乙醇酸、聚乳酸與聚乙醇酸之共聚物、聚ε-己內酯、聚羥基丁酸、聚原酸酯、聚縮醛、聚二氫哌喃、聚氰基丙烯酸酯及水凝膠之交聯或兩性嵌段共聚物。
某些具體例中組成物呈單位劑型諸如錠劑、丸劑、膠囊、粉劑、顆粒劑、滅菌非口服溶液或懸浮液、定量噴霧劑或液體噴霧劑、滴劑、安瓿、自動注射裝置或栓劑，用於口服、非口服、鼻腔、舌下或直腸給藥，或用於經吸入或吹入給藥。
替代地，組成物亦可呈現為適合於每星期一次或每月一次給藥之劑型；例如，活性化合物之不溶解鹽，諸如癸酸鹽，可適合於提供肌肉內注射用之長效製劑。
本文中之醫藥組成物，每劑量單位，如，錠劑、膠囊、粉劑、注射劑、一茶匙量、栓劑等，係含有如上述必需遞送之有效劑量之活性成分量。例如，本文中之醫藥組成物，每劑量單位可含有約10至約1000mg活性成分，如，約25至約600mg活性成分，如，約75至約400mg活性成分，如，約25、50、75、100、125、150、175、200、225、250、275、300、325、350、375、400、425、450、475、500、525、550、575或600mg或更多或其中之任何範圍。
本發明一些具體例中，適合使用於實踐本發明之胺甲酸酯化合物係為單獨給藥或與至少一種或多種其他化合物或治療劑合併給藥，如，與其他治療猝倒症及/或與猝倒症或猝睡症有關聯之其他障礙或症狀(如，白天過度嗜睡、入睡前幻覺及睡眠癱
瘓)之藥劑合併。治療猝倒症之治療劑的實例包含，而不限於，抗鬱劑(如，三環類(諸如氯米帕明(clomipramine)、丙咪嗪(imipramine)及普羅替林(protriptyline))及選擇性血清素再吸收抑制劑(諸如氟西汀(fluoxetine)、帕羅西汀(paroxetine)、舍曲林(sertraline)、西酞普蘭(citalopram))及羥丁酸鈉(γ-羥基丁酸酯[GHB])。治療白天過度嗜睡及其他猝睡症症狀之治療劑包含，而不限於，安非他命類(諸如右旋安非他命、甲基安非他命及呱醋甲酯(methylphenidate))、莫達非尼(modafinil)、阿莫達非尼(armodafinil)、阿托莫西汀(atomoxetine)及司立吉林(selegiline)。已知唯一能改善猝倒症及白天過度嗜睡兩者之藥物為羥丁酸鈉。
該方法包含給予需要治療之患者有效量之本文所揭露之胺甲酸酯化合物中之一種的步驟，而該胺甲酸酯化合物係與一種或多種有效量的其他化合物或治療劑組合，而該化合物或治療劑具有提供有益之組合效果，諸如加強本發明化合物之效用的能力。
醫藥上可接受之鹽類或酯類意指醫藥上可接受且具有所需藥理性質之鹽類或酯類。此種鹽類包含存在於化合物中之酸性質子能與無機或有機鹼反應而可形成之鹽類。適合之無機鹽類包含與鹼性金屬，如，鈉與鉀、鎂、鈣及鋁所形成者。適合之有機鹽類包含與有機鹼諸如胺鹼類，如，乙醇胺、二乙醇胺、三乙醇胺、胺基丁三醇、N-甲基葡糖胺等所形成者。醫藥上可接受之鹽類亦可包含酸加成鹽，而該酸加成鹽係親體化合物中之胺部分與無機酸(如，鹽酸及氫溴酸)及有機酸(如，乙酸、檸檬酸、順丁烯二酸及烷烴-及芳烴-磺酸諸如甲磺酸及苯磺酸)反應而形成
者。醫藥上可接受之酯類包含從存在於化合物中之羧基、磺醯氧基及膦氧基(phosphonoxy)所形成之酯類。有兩個酸性基存在時，醫藥上可接受之鹽或酯可為單酸單鹽或單酯或雙鹽或雙酯；同樣地，有多於兩個之酸基存在時，此類基團之一些或全部可經鹽化或酯化。
本發明中命名之化合物可以未鹽化或未酯化之形式，或鹽化及/或酯化之形式呈現，且此類化合物之命名意指包含初始(未鹽化及未酯化)化合物及其醫藥上可接受之鹽類或酯類兩者。本發明包含式(I)之醫藥上可接受之鹽或酯之形式。可存在不只一種晶形之式(I)之鏡像異構物，且亦同樣地包含於本發明。
本發明之醫藥組成物除了胺甲酸酯化合物之外，可視需要含有至少一種其他適用於治療猝倒症之治療劑。例如可將式(I)之胺甲酸酯化合物與其他化合物物理性組合為固定劑量複方而簡化彼等之給藥。
許多出版物說明調配醫藥組成物之方法諸如Pharmaceutical Dosage Forms：Tablets.Second Edition.Revised and Expanded.卷1-3,Lieberman et al.編輯；Pharmaceutical Dosage Forms：Parenteral Medications.卷1-2,Avis et al.編輯；及Pharmaceutical Dosage Forms：Disperse Systems.卷1-2,Lieberman et al.編輯；Marcel Dekker,Inc出版，通過引用將其各揭露之全部內容併入本文中並用於所有目的。
一般將醫藥組成物配製成滅菌、實質上等張的，且係完全遵照所有美國食品及藥物管理局之優良製造作業(GMP)規範。
本發明提供使用胺甲酸酯化合物供給治療哺乳類動物之猝倒症的方法。提供治療猝倒症所需之胺甲酸酯化合物量定義為治療或藥物有效劑量。此用途之劑量表及有效量，即，給藥或劑量方案取決於多種因素，包含疾病之階段、患者身體狀態、年齡等。為患者計算劑量方案時，亦考量給藥模式。
所屬技術領域之人士對於本揭露，不需做過多實驗即能夠決定用於實踐本發明之特定取代之胺甲酸酯化合物之治療有效量(請參照，如，Lieberman,Pharmaceutical Dosage Forms(卷1-3,1992)；Lloyd,1999,The Art,Science and Technology of Pharmaceutical Compounding；及Pickar,1999,Dosage Calculations)。
治療有效劑量亦為治療有益效用，在臨床術語上重要性超過任何毒性或有害副作用之劑量。進一步要注意的是對各特定之個體，必需根據個別需要及給藥或監督給藥化合物之人員的專業判斷而經時評估及調整具體劑量方案。
為了治療之目的，可通過一段延長時間之持續遞送，或以重複之給藥方案(如，以小時計、以天計或以星期計之重複給藥方案)而單次大劑量遞送本文所揭露之組成物或化合物予個體。本發明藥物配方可經，例如，每天一次或多次、每星期3次或每星期1次而給藥。本發明之具體例中，本發明藥物配方為每天經口服給藥1次或2次。
由此而論，生物活性劑之治療有效劑量可包含經延長之治療方案內之重複劑量，該重複劑量產生臨床顯著結果而提供猝倒症之治療。由此而論，決定有效量一般係以動物模型研究隨後經人體臨床試驗為基礎及經由決定顯著降低個體之標靶暴露
病徵或症狀之發生或嚴重性之有效劑量及給藥方案引導。在這方面之適當模型包含，例如，鼠科動物、大鼠、豬、貓、非人類靈長類及所屬領域習知之其他接受之動物模型個體。替代地，可使用生體外模型(如，免疫及組織病理分析)決定有效劑量。
使用此種模型，一般只需要普通計算及調整即可決定給予生物活性劑治療有效量之適當濃度及劑量(如，口服有效、鼻腔有效、經皮有效、靜脈有效或肌肉內有效而達到所需反應之量)。然而有效量可取決於所使用之特別化合物、給藥之模式、製劑之強度、給藥之模式及疾病症狀之進展而改變。另外，亦有與受治療之特定患者有關聯之因素，包含患者年齡、體重、膳食及給藥時間，而造成調整劑量之需要。
本發明之示例具體例中，配製化合物之單位劑型而用於標準給藥方案。依此方式，可將組成物照醫師的指示輕易地細分成較小的劑量。例如，單位劑量可製成裝成小包之粉劑、小玻璃瓶或安瓿及較佳為膠囊或錠劑形式。
本發明胺甲酸酯化合物之有效給藥可為，例如，口服或非口服劑量約0.01mg/kg/劑至約150mg/kg/劑。例如，給藥可為約0.1mg/kg/劑至約25mg/kg/劑，如，約0.2至約18mg/kg/劑，如，約0.5至約10mg/kg/劑。因此，活性成分之治療有效量可為，用於具有平均體重，例如，70kg之個體，例如，約1mg/天至約7000mg/天，如，約10至約2000mg/天，如，約50至約600mg/天，如，約10、25、50、75、100、125、150、175、200、225、250、275、300、325、350、375、400、425、450、475、500、525、550、575或600mg/天或更多或為其中之任何範圍。具體例
中，式I化合物係以劑量約150mg至約300mg而無賦形劑之膠囊形式給藥。
本發明之方法亦提供使用於供給治療猝倒症之檢測試劑盒。當包括一種或多種本發明胺甲酸酯化合物之醫藥組成物，與可能添加之一種或多種有益於治療之其他化合物經調配於適當之載體中之後，可放置於適當之容器中並標記而用於提供治療猝倒症。此外，也可將包括至少一種其他治療劑之另一種藥物放置於容器中並標記而用於治療指明之疾病。此種標記可包含，例如，關於各藥物給藥之量、次數及方法之指示。
於以下非限定之實施例中說明根據本發明之具體例。
對治療有猝睡症之個體白天過度嗜睡之ADX-N05的安全性及效能進行研究。該研究包含ADX-N05對在此研究中亦具患有猝倒症之猝睡症個體亞群之潛在效能的探索性分析。評估ADX-N05在患有猝倒症之個體亞群之主要及次要效能變量上之性能。此外，亦評估ADX-N05在降低猝倒事件數之效益。
該研究為雙盲、彈性標靶劑量、安慰劑對照、多中心、隨機、平行組之研究。成功完成篩選階段及基線階段之後，將個體隨機分至兩種治療組之其一並於12星期之治療期間，如表1所示接受ADX-N05或安慰劑(治療組#1：第1至4星期：ADX-N05 150mg/天；第5至12星期：ADX-N05 300mg/天；治療組#2：第1至12星期：安慰劑)。
開始12星期之治療期前，個體完成達28天之篩選階段，在這段時間期間進行所有篩選評估並中斷任何現有之猝睡症治療以及基線階段，包含於試驗場所之留宿，在這段時間期間得到基線效能及安全評估。治療階段期間，個體回到試驗場所完成1、2、4、6、8及12星期末之效能及安全評估；第4星期及第12星期就診亦包含試驗場所之留宿。在第12星期就診評估前，個體於第12星期就診時服用彼等之研究藥物最終劑量。個體在第13星期末返回作追蹤評估，且除非有任何顯著安全問題需要追蹤，否則該就診後個體即從研究退出。
研究之探測性指標為：(1)於第4星期及最後評估，服用ADX-N05相對於安慰劑之患有猝倒症個體亞群每星期猝倒發作中位數之基線改變量；及(2)患有猝倒症個體亞群之主要及次要效能指標。患者保留猝倒日誌而追蹤發作之數目。計算各治療組中患有猝倒症個體亞群之基線改變量，其為於第4星期及最後有效評估，服用ADX-N05相對於安慰劑之患有猝倒症個體亞群每星期猝倒發作於中位數之基線改變量。使用Wilcoxon等級和檢定比較兩治療組。
群體中總共有32位個體診斷為患有猝倒症，且係包含於猝倒症群體。一位個體(2002在安慰劑組)未完成基線猝倒症日誌而未包含於猝倒症日誌分析。
ADX-N05對猝倒症群體中主要及次要效能變數之效用示於表2(清醒度維持試驗(MWT))、表3(嗜睡度量表(ESS))、表4(臨床整體印象(CGI-C))及表5(患者整體印象(PGI-C))。
患有猝倒症個體亞群在第4星期及第12星期/最後評估，顯示前4個MWT試驗之平均值以及5個個別MWT試驗與整體群體之入睡潛伏期基線改變量有相似結果。而且，大多數ADX-N05組之個體相對於安慰劑組在各研究星期之CGI-C及PGI-C均經歷改善。治療組間在第12星期/最後評估之CGI-C(ADX-N05個體之94.1%相對於安慰劑個體之53.3%；p=0.0133)及PGI-C(ADX-N05個體之94.1%相對於安慰劑個體之53.3%；p=0.0133)皆有統計上之顯著差異。一致地觀察到在各研究星期經ADX-N05治療之個體相對於安慰劑個體平均ESS總評分之較大降低。此差異在第1星期及第12星期/最後評估為統計上顯著(第1星期降低6.8對2.4點，p=0.0170；及第12星期/最後評估降低9.8對2.5點，p=0.0010)。
表6提供在下列研究期間隨同計算之與基線相差之改變量及相應p-值一起報告之每星期猝倒發作數目總結：基線、第1至4星期、只第4星期、第5至12星期及只第12星期/最後評估。表7提供個體亞群之此等數據的總結，而該個體亞群報告於基線期間經歷每星期多於3次之猝倒發作。
包含所有猝倒症個體(N=31)時，用ADX-N05治療
未造成每星期猝倒事件與基線相差之中位數改變與安慰劑有明顯差異(表6)。此研究未特別地招募猝倒症個體，然而，結果猝倒症群體顯著地略為有病(基線每星期4猝倒事件中位數)。進行包含只有於基線每星期多於3次猝倒事件之個體之事後歸因分析時，顯示減少猝倒事件之趨向而有利於ADX-N05治療組(於第12星期/最後評估之每星期猝倒事件中位數之減少，ADX-N05之7相對於安慰劑之1.5)(表7)。超過一半之經ADX-N05治療之個體(6/11；55%)與安慰劑組之0%(0/6)比較，具有大於50%之每星期猝倒發作減少。
上述為本發明之說明，不當解釋為用以限制。本發明由下列申請專利範圍限定，也包含申請專利範圍其中之等同物。
本文引證之所有出版物、專利申請、專利及其他參考文獻均通過引用將其全部內容併入本文中而用於有關呈現引用之句子及/或段落之教導。
Claims (22)
- 一種治療有效量之式(I)化合物或其醫藥上可接受之鹽在用於製備治療猝倒症的藥物的用途，
- 如申請專利範圍第1項所述之用途，其中，x=0。
- 如申請專利範圍第1項所述之用途，其中，R1及R2為氫及x=0。
- 如申請專利範圍第1至3項中任一項所述之用途，其中，該式(I)化合物為實質上無其他鏡像異構物之式(I)之鏡像異構物，或其中一種式(I)之鏡像異構物佔多數之鏡像異構物混合物。
- 如申請專利範圍第4項所述之用途，其中，該式(I)之鏡像異構 物佔多數達約90%或更多。
- 如申請專利範圍第4項所述之用途，其中，該式(I)之鏡像異構物佔多數達約98%或更多。
- 如申請專利範圍第4項所述之用途，其中，該式(I)之鏡像異構物為式(Ia)之鏡像異構物：
- 如申請專利範圍第7項所述之用途，其中，該式(Ia)之鏡像異構物為(R)或(D)鏡像異構物。
- 如申請專利範圍第7項所述之用途，其中，該式(Ia)之鏡像異構物為(S)或(L)鏡像異構物。
- 如申請專利範圍第7項所述之用途，其中，該式(Ia)之鏡像異構物佔多數達約90%或更多。
- 如申請專利範圍第7項所述之用途，其中，該式(Ia)之鏡像異構物佔多數達約98%或更多。
- 如申請專利範圍第4項所述之用途，其中，該實質上無其他鏡像異構物之式(I)之鏡像異構物為式(Ib)化合物或為式(Ib)化合物佔多數之鏡像異構物混合物：
- 如申請專利範圍第12項所述之用途，其中，該式(Ib)化合物佔多數達約90%或更多。
- 如申請專利範圍第12項所述之用途，其中，該式(Ib)化合物佔多數達約98%或更多。
- 如申請專利範圍第1項所述之用途，其中，該猝倒症係與猝睡症有關。
- 如申請專利範圍第1項所述之用途，其中，該猝倒症係伴隨使個體下視丘分泌素濃度減少之症狀而繼發。
- 如申請專利範圍第16項所述之用途，其中，該症狀係選自由腦瘤、星狀細胞瘤、神經膠質母細胞瘤、神經膠質瘤、室管膜下瘤、顱咽管瘤、動靜脈畸形、缺血性事件、多發性硬化症、頭部外傷、腦部手術、腫瘤伴生症候群、Neimann-Pick氏症C型及腦炎所構成之群組。
- 如申請專利範圍第1項所述之用途，其中，該式(I)化合物之治療有效量為約0.01mg/kg/劑至約150mg/kg/劑。
- 如申請專利範圍第1項所述之用途，其中，該式(I)化合物之治療有效量為約1mg/天至約7000mg/天。
- 如申請專利範圍第1項所述之用途，其中，該式(I)化合物係口服給藥。
- 如申請專利範圍第1項所述之用途，其中，該式(I)化合物係以膠囊或錠劑之形式給藥。
- 如申請專利範圍第1項所述之用途，其中，該式(I)化合物係以劑量約150mg至約300mg且無任何賦形劑之膠囊形式給藥。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778998P | 2013-03-13 | 2013-03-13 | |
| US61/778,998 | 2013-03-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201919606A TW201919606A (zh) | 2019-06-01 |
| TWI684450B true TWI684450B (zh) | 2020-02-11 |
Family
ID=51530017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108107074A TWI684450B (zh) | 2013-03-13 | 2014-03-12 | 猝倒症之治療 |
| TW103108612A TWI663971B (zh) | 2013-03-13 | 2014-03-12 | 猝倒症之治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103108612A TWI663971B (zh) | 2013-03-13 | 2014-03-12 | 猝倒症之治療 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US9359290B2 (zh) |
| EP (1) | EP2968208B1 (zh) |
| JP (2) | JP6530741B2 (zh) |
| KR (1) | KR102192554B1 (zh) |
| CN (1) | CN105431142B (zh) |
| AU (1) | AU2014248849B2 (zh) |
| BR (1) | BR112015022197B1 (zh) |
| CA (1) | CA2905457A1 (zh) |
| DK (1) | DK2968208T3 (zh) |
| ES (1) | ES2927675T3 (zh) |
| HK (1) | HK1219236A1 (zh) |
| HR (1) | HRP20221018T1 (zh) |
| HU (1) | HUE060060T2 (zh) |
| MX (1) | MX2015012644A (zh) |
| MY (1) | MY177740A (zh) |
| PH (1) | PH12015502075B1 (zh) |
| PT (1) | PT2968208T (zh) |
| RU (2) | RU2019114940A (zh) |
| SG (1) | SG11201507121RA (zh) |
| SI (1) | SI2968208T1 (zh) |
| TW (2) | TWI684450B (zh) |
| WO (1) | WO2014164969A1 (zh) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006133393A1 (en) * | 2005-06-08 | 2006-12-14 | Sk Holdings Co., Ltd. | Treatment of sleep-wake disorders |
| EP2445490B1 (en) | 2009-06-22 | 2023-02-08 | SK Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| EP2968208B1 (en) * | 2013-03-13 | 2022-07-20 | Jazz Pharmaceuticals Ireland Limited | Treatment of cataplexy |
| KR102309836B1 (ko) | 2013-07-18 | 2021-10-12 | 에스케이바이오팜 주식회사 | 비만의 치료 |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CA3036071A1 (en) | 2016-09-06 | 2018-03-15 | Jazz Pharmaceuticals International Iii Limited | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| JP7074750B2 (ja) | 2016-10-06 | 2022-05-24 | ジャズ ファーマスティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール化合物およびその使用 |
| KR20200016889A (ko) | 2017-06-02 | 2020-02-17 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 과다 졸림증을 치료하기 위한 방법 및 조성물 |
| EP3661911A4 (en) | 2017-07-31 | 2021-04-14 | Jazz Pharmaceuticals Ireland Limited | CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF |
| KR20200053570A (ko) * | 2017-09-12 | 2020-05-18 | 오비드 테라퓨틱스 인크. | 기면증의 치료에서 가복사돌의 사용 |
| WO2019148181A1 (en) | 2018-01-29 | 2019-08-01 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) * | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| BR112021007019A2 (pt) * | 2018-10-15 | 2021-07-13 | Axsome Therapeutics, Inc. | uso de reboxetina para tratar narcolepsia |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| AU2020395082A1 (en) * | 2019-12-03 | 2022-06-09 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090312416A1 (en) * | 2005-06-08 | 2009-12-17 | Abdallah Ahnaou | Treatment of sleep-wake disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US178429A (en) * | 1876-06-06 | Improvement in hulling-machines | ||
| JPS58156351A (ja) * | 1982-03-11 | 1983-09-17 | Sumitomo Chem Co Ltd | メタクリル酸合成触媒の再生方法 |
| CZ285829B6 (cs) | 1993-06-10 | 1999-11-17 | Eli Lilly And Company | Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| DK0873308T3 (da) | 1996-10-10 | 2002-04-22 | Sk Corp | O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte |
| WO1998017636A1 (en) | 1996-10-22 | 1998-04-30 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| GB0109103D0 (en) * | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| US20030207857A1 (en) | 2001-04-11 | 2003-11-06 | Adam Mavis D. | Phenyl heterocyclyl ethers |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| CN1960981A (zh) * | 2004-03-31 | 2007-05-09 | 詹森药业有限公司 | 作为组胺h3受体调节剂的非咪唑杂环化合物 |
| CA2579576A1 (en) * | 2004-09-07 | 2006-03-16 | Orphan Medical, Inc. | Improved ghb compositions |
| EP1819328A1 (en) | 2004-10-28 | 2007-08-22 | SK Corporation | Adjunctive therapy for depression |
| KR101335942B1 (ko) | 2005-06-22 | 2013-12-04 | 에스케이바이오팜 주식회사 | 성기능 장애의 치료 |
| CN101272776B (zh) | 2005-07-26 | 2012-10-03 | 詹森药业有限公司 | 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途 |
| FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
| MX2009003926A (es) | 2006-10-13 | 2009-06-26 | Janssen Pharmaceutica Nv | Composiciones de fenilalquilamino-carbamato. |
| JP2010510175A (ja) * | 2006-11-10 | 2010-04-02 | ディメリックス・バイオサイエンス・ピーティーワイ・リミテッド | 甲状腺刺激ホルモン放出ホルモン受容体−オレキシン受容体のヘテロダイマー／オリゴマー |
| EP2445490B1 (en) | 2009-06-22 | 2023-02-08 | SK Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| BR112012010648A2 (pt) | 2009-11-06 | 2020-12-01 | Sk Biopharmaceuticals Co., Ltd. | uso de compostos na preparação de composições farmacêuticas para tratar síndrome de fibromialgia e composição farmacêutica |
| MX2012005258A (es) | 2009-11-06 | 2012-06-19 | Sk Biopharmaceuticals Co Ltd | El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad. |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| EP2968208B1 (en) * | 2013-03-13 | 2022-07-20 | Jazz Pharmaceuticals Ireland Limited | Treatment of cataplexy |
-
2014
- 2014-03-12 EP EP14778088.6A patent/EP2968208B1/en active Active
- 2014-03-12 PT PT147780886T patent/PT2968208T/pt unknown
- 2014-03-12 MX MX2015012644A patent/MX2015012644A/es unknown
- 2014-03-12 DK DK14778088.6T patent/DK2968208T3/da active
- 2014-03-12 MY MYPI2015703166A patent/MY177740A/en unknown
- 2014-03-12 CA CA2905457A patent/CA2905457A1/en not_active Abandoned
- 2014-03-12 US US14/205,423 patent/US9359290B2/en active Active
- 2014-03-12 WO PCT/US2014/023969 patent/WO2014164969A1/en active Application Filing
- 2014-03-12 KR KR1020157027978A patent/KR102192554B1/ko active IP Right Grant
- 2014-03-12 ES ES14778088T patent/ES2927675T3/es active Active
- 2014-03-12 JP JP2016501395A patent/JP6530741B2/ja active Active
- 2014-03-12 BR BR112015022197-1A patent/BR112015022197B1/pt active IP Right Grant
- 2014-03-12 HR HRP20221018TT patent/HRP20221018T1/hr unknown
- 2014-03-12 TW TW108107074A patent/TWI684450B/zh active
- 2014-03-12 HU HUE14778088A patent/HUE060060T2/hu unknown
- 2014-03-12 SG SG11201507121RA patent/SG11201507121RA/en unknown
- 2014-03-12 AU AU2014248849A patent/AU2014248849B2/en active Active
- 2014-03-12 RU RU2019114940A patent/RU2019114940A/ru not_active Application Discontinuation
- 2014-03-12 SI SI201431991T patent/SI2968208T1/sl unknown
- 2014-03-12 CN CN201480027152.9A patent/CN105431142B/zh active Active
- 2014-03-12 RU RU2015143610A patent/RU2689984C2/ru active
- 2014-03-12 TW TW103108612A patent/TWI663971B/zh active
-
2015
- 2015-09-11 PH PH12015502075A patent/PH12015502075B1/en unknown
-
2016
- 2016-05-09 US US15/149,478 patent/US9585863B2/en active Active
- 2016-06-23 HK HK16107350.1A patent/HK1219236A1/zh unknown
-
2017
- 2017-01-30 US US15/419,133 patent/US10259780B2/en active Active
-
2019
- 2019-03-20 US US16/359,446 patent/US11072579B2/en active Active
- 2019-05-17 JP JP2019093823A patent/JP2019147830A/ja active Pending
-
2021
- 2021-07-23 US US17/383,707 patent/US11713292B2/en active Active
-
2023
- 2023-06-19 US US18/337,299 patent/US20230416195A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090312416A1 (en) * | 2005-06-08 | 2009-12-17 | Abdallah Ahnaou | Treatment of sleep-wake disorders |
Non-Patent Citations (1)
| Title |
|---|
| WC. Houghton,et al."Pharmacotherapy for cataplexy",Sleep Medicine Reviews,2004, 8, 355~366. JD. Amsterdam,et al."A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A—a putative, new antidepressant",Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002) 1333~ 1338. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI684450B (zh) | 猝倒症之治療 | |
| JP6824315B2 (ja) | 肥満の治療 | |
| US9980927B2 (en) | Use of tapentadol for inhibiting and/or treating depression and anxiety | |
| RU2557533C2 (ru) | Способы лечения синдрома фибромиалгии | |
| TWI707677B (zh) | 肥胖之治療 | |
| US10695432B2 (en) | Solid solution compositions and use in severe pain | |
| WO2024102718A1 (en) | Compositions and methods for treating insomnia | |
| EP3854391B1 (en) | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder | |
| TW200533361A (en) | Medicinal composition for treating allergic symptoms | |
| CN113747888A (zh) | 用于增强4-氨基苯酚衍生物的组合物和方法 |